CG
SGMO

Cutler Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cutler Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,900
Closed -$1K – 5597
2022
Q1 		$1K Buy
+7,900
New +$47K ﹤0.01% 5065
2018
Q1 		– Sell
-11,500
Closed -$62K – 5128
2017
Q4 		$62K Sell
11,500
-6,700
-37% -$99.7K ﹤0.01% 1710
2017
Q3 		$117K Buy
18,200
+7,100
+64% +$78.5K ﹤0.01% 1542
2017
Q2 		$30K Buy
11,100
+3,700
+50% +$23.7K ﹤0.01% 3007
2017
Q1 		$8K Buy
+7,400
New +$29.7K ﹤0.01% 4298
2016
Q4 		– Sell
-47,500
Closed -$7K – 7225
2016
Q3 		$7K Buy
47,500
+16,400
+53% +$83.4K ﹤0.01% 4629
2016
Q2 		$6K Sell
31,100
-113,200
-78% -$721K ﹤0.01% 4774
2016
Q1 		$42K Buy
144,300
+81,500
+130% +$489K ﹤0.01% 2517
2015
Q4 		$31K Buy
+62,800
New +$484K ﹤0.01% 2966

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's SGMO Position: Q1 2023 in Review

Cutler Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2023, closing a stake of 700 shares — an estimated $2K sold.

Cutler Group first reported a position in SGMO in Q4 2015 and held it in 13 quarters. The position peaked at $553K in Q4 2015. 179 funds tracked by Wall St. Rank hold SGMO as of Q1 2023.

  • Cutler Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 700 SANGAMO THERAPEUTICS INC shares in Q1 2023, an estimated $2K.
  • Cutler Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2015 and held it in 13 quarters.
  • Cutler Group's SANGAMO THERAPEUTICS INC position peaked at $553K in Q4 2015.
  • 179 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.